K. Kleiber

Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.

C. Duhem, F. Ries, M. Dicato, 1997, Seminars in oncology.

FHL2 Regulates Cell Cycle-Dependent and Doxorubicin-Induced p21Cip1/Waf1 Expression in Breast Cancer Cells

K. Strebhardt, V. Wixler, M. Kaufmann, 2007, Cell cycle.

Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation

B. Bay, K. Itahana, Y. Itahana, 2016, eLife.

The biological relevance of FHL2 in tumour cells and its role as a putative cancer target.

K. Strebhardt, B. Martin, K. Kleiber, 2007, Anticancer research.

Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.

D. Larsimont, M. Piccart, F. Cardoso, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.